Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Royal DSM N.V.
  6. News
  7. Summary
    DSM   NL0000009827

ROYAL DSM N.V.

(DSM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royal DSM N : DSM acquires next-generation eubiotics platform start-up

07/27/2021 | 02:10am EDT

Heerlen, NL, 27 Jul 2021 08:00 CEST

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has acquired Midori USA, Inc. ('Midori'), a biotechnology start-up with a novel precision platform developing breakthrough targeted eubiotics that improve the health and environmental impact of animals. DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.

Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals. These glycans provide an effective and consistent impact on animal gut health, leading to improved nutrient utilization from feed and improved animal health. Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.

The use of eubiotics has grown significantly as farming practices shift to become more sustainable and along with the need to provide antibiotic alternatives. Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group).

DSM will launch its first targeted glycan - Symphiome™ - later this year. This unique eubiotic will be the first product from DSM's collaboration with Midori, leveraging functional modulation of the gut microbiome to improve the gut health, feed efficiency and welfare of poultry, while reducing the use of antibiotics and lowering the environmental emissions of poultry farming. Symphiome™ will be the second novel mode of action eubiotic product that DSM will bring to the market after the successful launch of Balancius®, a breakthrough innovation that improves the overall digestive health of animals.

Disclaimer

Koninklijke DSM NV published this content on 27 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2021 06:09:03 UTC.


© Publicnow 2021
All news about ROYAL DSM N.V.
09/14DSM Starts A Review of Strategic Options
CI
09/14ROYAL DSM N : Koninklijke DSM N.V., - DSM accelerates its strategic journey to a..
PU
09/14Europe ends flat as miners, luxury stocks weigh; inflation optimism cools
RE
09/14ROYAL DSM N : Koninklijke DSM N.V., - DSM announces food system commitments to s..
PU
09/14ROYAL DSM N : DSM prefers direct sale of materials division, CEO says
RE
09/14ROYAL DSM N : Dutch DSM to exit materials to focus on food, health and climate
RE
09/14ROYAL DSM N : DSM Begins Strategic Review of Materials Businesses in Health-Focu..
MT
09/14ROYAL DSM N : DSM Targets Livestock Emission Cuts In Set of Food System Commitme..
MT
09/14ROYAL DSM N : DSM announces food system commitments to set a healthier future fo..
PU
09/14ROYAL DSM N : DSM accelerates its strategic journey to a fully focused Health, N..
PU
More news
Analyst Recommendations on ROYAL DSM N.V.
More recommendations
Financials
Sales 2021 8 958 M 10 531 M 10 531 M
Net income 2021 1 500 M 1 763 M 1 763 M
Net Debt 2021 1 097 M 1 290 M 1 290 M
P/E ratio 2021 21,4x
Yield 2021 1,36%
Capitalization 31 868 M 37 492 M 37 464 M
EV / Sales 2021 3,68x
EV / Sales 2022 3,47x
Nbr of Employees 21 173
Free-Float 91,1%
Chart ROYAL DSM N.V.
Duration : Period :
Royal DSM N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL DSM N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 186,60 €
Average target price 178,47 €
Spread / Average Target -4,35%
EPS Revisions
Managers and Directors
Dimitri de Vreeze Co-Chief Executive Officer & COO
Géraldine Matchett Co-Chief Executive Officer & CFO
Thomas Leysen Chairman-Supervisory Board
Eileen A. Kennedy Member-Supervisory Board
Pradeep Pant Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ROYAL DSM N.V.31.53%37 378
SHIN-ETSU CHEMICAL CO., LTD.16.71%80 248
BASF SE0.14%70 346
DUPONT DE NEMOURS, INC.-1.55%36 619
PIDILITE INDUSTRIES LIMITED36.11%16 588
ASAHI KASEI CORPORATION19.39%15 899